NCT03598192

Brief Summary

The anterior abdominal wall from below the xiphoid to infraumbilical area is dominated by the sensory nerves which originate from the anterior rami of the thoracolumbar spinal nerves from T6-L1. The branches nerves from T7-T12 are between aponeurosis internal oblique and transversus abdominal muscle. They can be approached with the ultrasound guidance at subcostal and lateral abdominal wall position. The bilateral transversus abdominis plane (TAP) block has been demonstrated effectiveness and safety in postoperative analgesia to the under abdominal surgery. However, the effect of one to the upper abdominal surgery is unclear. The four points TAP block has been described the first in 2010. The effect of the four points TAP block in postoperative analgesia to the upper abdominal surgery has been reported in recent years. Besides, the effect of thoracic paravertebral block (PVB) in postoperative analgesia to liver resection was also reported. The both techniques have been performing in some studies. The effect and safety of the both techniques have been reported. However, the evidence level is still weak. The investigators need to find a technique, which has effectiveness as well as safety to replace the epidural analgesia, which was confirmed that had many complications, in postoperative analgesia to the hepatectomy. The investigators hypothesized that the four points TAP block under the ultrasound guidance has more effectiveness than the thoracic paravertebral block in postoperative analgesia to the hepatectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 3, 2018

Completed
23 days until next milestone

First Posted

Study publicly available on registry

July 26, 2018

Completed
20 days until next milestone

Study Start

First participant enrolled

August 15, 2018

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2020

Completed
Last Updated

January 12, 2021

Status Verified

January 1, 2021

Enrollment Period

17 days

First QC Date

July 3, 2018

Last Update Submit

January 11, 2021

Conditions

Keywords

HepatectomyTransversus abdominis plane block (TAP block)Paravertebral blockPostoperative analgesiaLiver resection

Outcome Measures

Primary Outcomes (1)

  • The consumption of sulfentanil (mean)

    The consumption of sufentanil is total dose of sufentanil which the participant used during 24 hours. Sufentanil is intravenously infused with PCA, with single dose 1 mcg, limit dose 8 mcg per a hour, and lockout time 5 minutes.

    24 hours

Secondary Outcomes (3)

  • The complications of technique (frequency)

    24 hours

  • Side-effect of sulfentanil (frequency)

    48 hours

  • Satisfaction (mean)

    24 hours

Study Arms (2)

TAP group

EXPERIMENTAL

The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side. Drug: ropivacaine 0.375% 40 ml (maximum dose \<= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours.

Procedure: TAPDrug: RopivacaineDrug: Sufentanil

PVB group

EXPERIMENTAL

The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose \<= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.

Procedure: PVBDrug: RopivacaineDrug: Sufentanil

Interventions

TAPPROCEDURE

The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%

Also known as: The four points TAP block
TAP group
PVBPROCEDURE

The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%

Also known as: The paravertebral block
PVB group

Ropivacaine has been treated the both group

Also known as: have not been specified
PVB groupTAP group

Sufentanil has been included in Arm/Group Descriptions

Also known as: Sufentanil PCA
PVB groupTAP group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects has selective hepatectomy
  • Subjects has had II-III of Anesthesiologists Society Americans

You may not qualify if:

  • History of chronic pain
  • History of tolerance opioids
  • History of psychology disorder
  • Allergic to ropivacaine or opioids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Binh Huynh

Ho Chi Minh City, Ho Chi Minh, 70000, Vietnam

Location

MeSH Terms

Conditions

Liver DiseasesDisease

Interventions

RopivacaineSufentanil

Condition Hierarchy (Ancestors)

Digestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesFentanylPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Binh V Huynh, Mr

    Nhan dan Gia Dinh Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The TAP group will be performed the four points TAP block under the ultrasound guidance with the ultrasound machine of Logiq E, and linear 12S probe. The participants will be performed TAP block at subcostal and lateral abdominal wall at right and left side with stimuplex needle (sized 18G, length 100 mm). The investigators will approach position between aponeurosis internal oblique and transversus abdominal muscle with in-plane real-time ultrasound technique. The investigators will inject 10 ml of ropivacaine 0.375% at each one. Then, the investigators will access one catheter at TAP at right side to continuously infuse ropivacaine 0.375% during 48 hours after surgery. PVB group: the investigators will access one catheter into the right thoracic paravertebral space at T7 before beginning general anesthesia. At the end of surgery, the investigators will inject 20 ml of ropivacaine 0.5% through catheter, and continuously infuse ropivacaine 0.25% during 48 hours after surgery.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of Anesthesiology

Study Record Dates

First Submitted

July 3, 2018

First Posted

July 26, 2018

Study Start

August 15, 2018

Primary Completion

September 1, 2018

Study Completion

July 30, 2020

Last Updated

January 12, 2021

Record last verified: 2021-01

Locations